Background: Few Chinese study compared the impacts of idarubicin and daunorubicin based "3+7" intensive chemotherapies on early and long-term outcomes of AML patients through exploring their real-world data.
Patients And Methods: Our none promyelocytic AML patients inducted with "3+7" regimens were studied to find out the factors relating with induction response and long term survival.
Results: Idarubicin induction was related with less chemotherapy refractory rate comparing with daunorubicin induction (10% vs 25%, P = 0.02). But cytogenetic molecular risk classification was the only independent factor relating with achieving CR after initial induction or chemotherapy refractory (P = 0.000 and 0.036). Both to overall survival (OS) and progress free survival (PFS), having transplantation and chemotherapy refractory were independent factors related, MLL rearrangement and DNA methylating related genes' mutations as well. CR at time of transplantation and MLL rearrangement were independent factors relating both with OS after transplantation and relapse free survival after transplantation.
Conclusion: Traditional "3+7" chemotherapy regimen with idarubicin plays better in CR induction than that with daunorubicin. But the patient's long-term survival related with clinical practice aspects, like having stem cell transplantation, as well as genetic alterations equally, like MLL rearrangement and DNA methylating related genes' mutations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s40360-025-00839-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Loss of SMAD1 in acute myeloid leukemia with and fusion genes.
Front Oncol
January 2025
Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
Introduction: -rearrangements define a subclass of acute leukemias characterized by a distinct gene expression signature linked to the dysfunctional oncogenic fusion proteins arising from various chromosomal translocations involving the (also known as ) gene. Research on the disease pathomechanism in -rearranged acute leukemias has mainly focused on the upregulation of the stemness-related genes of the -family and their co-factor .
Results: Here we report the and fusion gene-dependent downregulation of , a TGF-β signaling axis transcription factor.
and mRNA expression-based risk stratification of acute Myeloid Leukemia.
Leuk Res Rep
December 2024
Independent Researcher, Gimpo-si, Gyeonggi-do 10090, South Korea.
Prognostication of acute myeloid leukemia (AML) at initial diagnosis relies on identification of pre-determined underlying genetic abnormalities. Nevertheless, the disease course of AML remains highly unpredictable and robust reliable prognostic biomarkers for newly diagnosed AML are lacking. We retrospectively explored two publicly available AML RNA-Seq datasets and found that inferior overall survival was associated with high- and low- transcript levels (" / ") compared to low- and high- transcript levels (" / ") in adult AML patients, with a hazard ratio for death of at least 2.
View Article and Find Full Text PDFBIMSSA: enhancing cancer prediction with salp swarm optimization and ensemble machine learning approaches.
Front Genet
January 2025
Department of Mechatronics Engineering, Parul Institute of Technology, Parul University, Vadodara, Gujarat, India.
Background: Cancer rates are rising rapidly, causing global mortality. According to the World Health Organization (WHO), 9.9 million people died from cancer in 2020.
View Article and Find Full Text PDFThe clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience.
BMC Pharmacol Toxicol
January 2025
Department of Hematology, Zhujiang Hospital of Southern Medical University, No. 253, Gongye Road, Haizhu District, Guangzhou, 510280, China.
Background: Few Chinese study compared the impacts of idarubicin and daunorubicin based "3+7" intensive chemotherapies on early and long-term outcomes of AML patients through exploring their real-world data.
Patients And Methods: Our none promyelocytic AML patients inducted with "3+7" regimens were studied to find out the factors relating with induction response and long term survival.
Results: Idarubicin induction was related with less chemotherapy refractory rate comparing with daunorubicin induction (10% vs 25%, P = 0.
ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink proteomics approach.
Clin Proteomics
January 2025
Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan.
Background: The standard "7 + 3" induction results in 30% of de novo acute myeloid leukemia (AML) patients not achieving complete remission (CR). We aimed to utilize the Olink platform to compare the bone marrow plasma proteomic profiles of newly diagnosed de novo AML patients who did and did not achieve CR following "7 + 3" induction treatment.
Methods: This prospective study included 43 untreated AML patients, stratified into CR (n = 29) and non-CR (n = 14) groups based on their response to "7 + 3" induction therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!